We have previously shown that the variable domains of the monoclonal antibody anti-Tac [anti-Tac(Fv)J can be fused t o derivatives of Pseudomonas exotoxin (PE) or diphtheria toxin (DT) t o produce recombinant immunotoxins that kill interleukin-2 (IL-2) receptor-bearing cells. We now report that two of these single-chain recombinant immunotoxins, anti-Tac(Fv)-PE4OKDEL and DT388-anti-Tac(Fv), are cytotoxic toward peripheral blood mononuclear cells (PBMCs) from patients with chronic lymphocytic leukemia (CLL). In anti-Tac(Fv)-PE4OKDEL. anti-Tac(Fv) is genetically fused t o the amino terminus of PE4OKDEL. a recombinant form of PE which contains amino acids 253-608 of PE and the -KDEL mutation at the carboxyl terminus. In DT388-anti-Tac(Fv), anti-Tac(Fv) is fused t o the carboxyl terminus of the first 388 amino acids of DT. PBMCs from 14 patients were incubated with the recombinant toxins for 60 hours, and [3H]-leucine incorporation was measured. Anti-Tac(Fv)-PE40KDEL was cytotoxic t o 7 of the 14 patient samples, with half-maximal inhibition of HRONIC lymphocytic leukemia (CLL) is the most C common type of leukemia diagnosed in the United States, accounting for 30% of the leukemias and 10,000 new cases annually.' Because of its long natural course, it is by far the most prevalent form of leukemia. However, no curative therapy exists and most patients eventually die of the disease.2 Cells from a high percentage of patients with CLL have been found to express both p55 and p75 components of the interleukin-2 (IL-2) recept0r,37~ despite the usual B-cell origin of this neoplasm. Because normal resting human cells express few if any IL-2 receptors, the presence of such receptors on CLL cells represents a potential target for therapy, particularly with growth factor receptor ligands connected to toxins. CLL may be an especially appropriate disease for targeted toxin therapy, because cells in bone marrow (BM), peripheral blood, and even spleen should be assessable to intravascular proteins. Moreover, patients with CLL suffer a humoral immune defect that might lessen the immune response toward the toxin? Indeed, the recombinant fusion between IL-2 and truncated diphtheria toxin, DABa61L-2,6 has induced remission in a CLL patient even after repeated cycle^.^ Pseudomonas exotoxin (PE) is a 66-Kd protein which, like diphtheria toxin (DT), kills cells by binding to a receptor, internalizing via a coated pit, translocating its active fragment into the cytosol, and enzymatically adenosine diphosphate (ADP)-ribosylating elongation factor-2 (EF2).8 The x-ray crystallographic structure of PE indicates three major domains, and mutational analysis has elucidated which domains are responsible for the several steps necessary to kill c e l l~.~J~ Domain Ia, composed of amino acids 1 through 252, functions to bind the toxin to the PE receptor. Domain I11 (amino acids 400 through 613) contains the enzymatic activity that ADP ribosylates EF2. Domain I1 (amino acids 253 through 364) undergoes proteolytic processing and is responsible for translocating to the cytosol the 37-Kd carboxyl terminus of PE that contains the ADP ribosylating activity. DT also undergoes proteolytic processing," but its amino terminus contains the ADP ribosylating activity and is translocated to the cytosol. Accordingly, in chimeric DT-containing toxins such as DAB486IL-2,6 DAB486MSH,12 and DAB486EGF,13 the ligand replaces the toxin's binding domain at the carboxyl terminus. Conversely, in PE-containing chimeric toxins, such as IL-2-PE4014 and CD4-PE40,15 the ligand replaces the toxin's binding domain at the amino terminus.
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We have previously shown that the variable domains of the monoclonal antibody anti-Tac [anti-Tac(Fv)J can be fused t o derivatives of Pseudomonas exotoxin (PE) or diphtheria toxin (DT) t o produce recombinant immunotoxins that kill interleukin-2 (IL-2) receptor-bearing cells. We now report that two of these single-chain recombinant immunotoxins, anti-Tac(Fv)-PE4OKDEL and DT388-anti-Tac(Fv), are cytotoxic toward peripheral blood mononuclear cells (PBMCs) from patients with chronic lymphocytic leukemia (CLL). In anti-Tac(Fv)-PE4OKDEL. anti-Tac(Fv) is genetically fused t o the amino terminus of PE4OKDEL. a recombinant form of PE which contains amino acids 253-608 of PE and the -KDEL mutation at the carboxyl terminus. In DT388-anti-Tac(Fv), anti-Tac(Fv) is fused t o the carboxyl terminus of the first 388 amino acids of DT. PBMCs from 14 patients were incubated with the recombinant toxins for 60 hours, and [3H]-leucine incorporation was measured. Anti-Tac(Fv)-PE40KDEL was cytotoxic t o 7 of the 14 patient samples, with half-maximal inhibition of HRONIC lymphocytic leukemia (CLL) is the most C common type of leukemia diagnosed in the United States, accounting for 30% of the leukemias and 10,000 new cases annually.' Because of its long natural course, it is by far the most prevalent form of leukemia. However, no curative therapy exists and most patients eventually die of the disease.2 Cells from a high percentage of patients with CLL have been found to express both p55 and p75 components of the interleukin-2 (IL-2) recept0r,37~ despite the usual B-cell origin of this neoplasm. Because normal resting human cells express few if any IL-2 receptors, the presence of such receptors on CLL cells represents a potential target for therapy, particularly with growth factor receptor ligands connected to toxins. CLL may be an especially appropriate disease for targeted toxin therapy, because cells in bone marrow (BM), peripheral blood, and even spleen should be assessable to intravascular proteins. Moreover, patients with CLL suffer a humoral immune defect that might lessen the immune response toward the toxin? Indeed, the recombinant fusion between IL-2 and truncated diphtheria toxin, DABa61L-2,6 has induced remission in a CLL patient even after repeated cycle^.^ the 14 samples, with lCms ranging from less than 1 t o 250 ng/mL. DT388-IL-2, in which the first 388 amino acids of DT are attached to IL-2, was marginally cytotoxic toward only 4 of 13 CLL samples tested with ICms ranging from 100 t o 550 ng/mL. Trypan blue staining of cells from several patients indicated that inhibition of protein synthesis correlated with cell death. Binding assays using [3H]-anti-Tac indicated that the CLL cells from nine of the patients contained between 400 and 2,500 sites per cell. Cells from another patient, which were resistant t o both anti-Tac(Fv)-PE40KDEL and DT388-antiTac(Fv), had less than 100 sites per cell. We conclude that anti-Tac(Fv)-PE40KDEL and DT388-anti-Tac(Fv) can kill CLL cells which have low numbers of IL-2 receptors, and should be investigated further for therapy of this disease. This is a US government work. There are no restrictions on its use.
Pseudomonas exotoxin (PE) is a 66-Kd protein which, like diphtheria toxin (DT), kills cells by binding to a receptor, internalizing via a coated pit, translocating its active fragment into the cytosol, and enzymatically adenosine diphosphate (ADP)-ribosylating elongation factor-2 (EF2).8 The x-ray crystallographic structure of PE indicates three major domains, and mutational analysis has elucidated which domains are responsible for the several steps necessary to kill c e l l~.~J~ Domain Ia, composed of amino acids 1 through 252, functions to bind the toxin to the PE receptor. Domain I11 (amino acids 400 through 613) contains the enzymatic activity that ADP ribosylates EF2. Domain I1 (amino acids 253 through 364) undergoes proteolytic processing and is responsible for translocating to the cytosol the 37-Kd carboxyl terminus of PE that contains the ADP ribosylating activity. DT also undergoes proteolytic processing," but its amino terminus contains the ADP ribosylating activity and is translocated to the cytosol. Accordingly, in chimeric DT-containing toxins such as DAB486IL-2,6 DAB486MSH,12 and DAB486EGF,13 the ligand replaces the toxin's binding domain at the carboxyl terminus. Conversely, in PE-containing chimeric toxins, such as IL-2-PE4014 and CD4-PE40,15 the ligand replaces the toxin's binding domain at the amino terminus.
We have recently reported the activities of recombinant toxins made from a derivative of the monoclonal antibody (MoAb) anti-Tac, which binds to the p55 subunit of the IL-2 receptor. Using recombinant DNA techniques we fused the variable heavy chain (V,) and light chain (V,) regions of anti-Tac to each other through a peptide linker to make a single chain antigen binding protein. This was in turn fused to domains I1 and 111 of PE, and the resulting chimeric toxin was termed anti-Tac(Fv)-PE40. 16 The recombinant immunotoxin anti-Tac(Fv)-PE40 was cytotoxic toward cells bearing p55 such as T-cell leukemia cell lines,16 activated human lymphocyte^,'^ and fresh cells from patients with adult T-cell leukemia (ATL),lS but not toward normal lymphocytes. To improve the activity of the toxin, we mutated the carboxyl terminus from -REDLK to -D E L , and found that anti-Tac(Fv)-PE40KDEL was several-fold more cytotoxic than anti-Tac(Fv)-PE40 toward target cells. 19 Another recombinant immunotoxin was made using diphtheria toxin by fusing anti-Tac(Fv) to the carboxyl terminus of the first 388 amino acids of DT. A similar truncated form of DT had been previously shown to make an active toxin when fused with IL-2.20 DT388-anti-Tac(Fv), like antiTac(Fv)-PE40, was also cytotoxic toward p55 bearing cells. 21 We also made DT388-IL-2, which contains IL-2 instead of anti-Tac(Fv) at the carboxyl terminus of the first 388 amino acids of DT.22
The goal of the present study was to determine the cytotoxic activities of anti-Tac(Fv)-PE40, anti-Tac(Fv)-PE40KDEL, DT388-anti-Tac(Fv), and DT388-IL-2 toward malignant cells isolated from patients with CLL.
MATERIALS AND METHODS
Patients. Fourteen CLL patients were examined. One of the 14 patients had prolymphocytic leukemia (patient 1); the remainder had the usual type of B-cell CLL. Table 1 gives the clinical characteristics of the patients.
As shown in respectively. The plasmids were expressed in Escherichia coli and the recombinant proteins purified as described.21 pVC70108M and pVC70108D f+T encode ADP-ribosylation defective mutants of anti-Tac(Fv)-PE40 in which Glu-553 has either been replaced with an aspartate residue or deleted, respectively? In pVC70108M, the codon encoding Asp-553 is 5'-GAC-3'. pRK7010841M, encoding anti-Tac(Fv)-PE40KDEL carrying an Asp-553 mutation, was constructed using polymerase chain reaction (PCR). The primers and procedure used were the same as those used to construct pVC49415 f+T,24 except that pVC70108M was used as the template. The 0.35-kb insert obtained after cutting the amplified fragment with BamHI and EcoRI was ligated to the 4.5-kb EcoRI-BamHI fragment of pRK70108D f+T, resulting in pRK7010841M.
pRK7010841M, encoding anti-Tac(F~)-PE40KDEL~~p~~~, was exRecombinant toxins and control molecules. pressed and the recombinant protein purified as describedJl All toxins used were greater than 95% pure by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (data not shown). Protein concentrations of toxins were determined by the Bradford assay using bovine serum albumin as a standard (Pierce, Rockford, IL), a method which for molecules of this type agrees well with determination of protein concentration by amino acid ana1y~is.I~ Anti-Tac was purified by Hazleton Laboratories (Vienna, VA) and H o f i a n n La Roche (Nutley, NJ). UPC-10 was purchased from Sigma (St Louis, MO). The LL2 MoAb was provided by Immunomedics (Newark, NJ). Fluorescent activated cell sorting (FACS) analysis was performed by Fast Systems (Gaithersburg, MD).
HUT-102 cells were maintained in RPMI containing 10% heat-inactivated fetal bovine serum (FBS). Anticoagulated venous blood was obtained from patients and used for experiments within 24 hours. The blood was diluted with phosphatebuffered saline (PBS), centrifuged over Ficoll (Organon Teknika, Durham, NC), and the mononuclear cells used for cytotoxicity assays.
Cells were incubated with toxins at 1 X lo6 cells/mL in leucine-poor media (88% leucine-free RPMI, 2% RPMI containing leucine 50 ug/ml, and 10% FBS) in 96-well plates containing 0.1 mL per well. After 60 hours, each well was pulsed with 2 pCi of [3H]-leucine diluted to 0.05 mL with leucine-free RPMI. After 6 to 8 hours of labeling, the cells were harvested onto protein-binding glass fiber filters and leucine incorporation determined with a Betaplate (Pharmacia-LKB, Gaithersburg, MD) scintillation counter. The medians of triplicate experiments, which usually varied from their means by less than 5%, were used for calculations. Before calculating ICsos, all values obtained with and without toxin addition were reduced by the level of [3H]-leucine incorporation in cells treated with cycloheximide 10 p,g/mL. This was done to correct for [3H]-leucine accumulating in the absence of protein synthesis. HUT-102 cells were assayed like the patient cells, except that the cell density was 4 x 105/mL, the volume per well was 0.2 mL, the incubation time with toxins was 16 hours, and the cells were pulsed with only 1 pCi of [3H]-leucine per well for 3 to 4 hours before harvesting.
CLL peripheral blood mononuclear cells (PBMCs) were incubated with toxins as described above for 1 week instead of 60 hours. Cells were diluted 1:l with 0.2% trypan blue, and the number of viable cells determined by light microscopy. The medians of triplicate experiments, which usually varied from their means by less than lo%, were used for data analysis.
Cells from patients were washed twice with binding buffer (Dulbecco's modified Eagle's medium [DMEM] containing 50 mmol/L BES pH 6.8 and bovine serum albumin The r2 value of the linear regression of the points in each Scatchard plot was 2.9.
Washed PBMCs from CLL patients were added to 96-well plates, as described above for binding assays. To the cells was then added 0.05 mL of binding buffer containing a constant amount of humanized [3H]-anti-Tac and varying amounts of either anti-Tac(Fv)-PE40, anti-Tac(Fv)-PE40KDEL, or DT388-anti-Tac(Fv). After equilibrating at 4°C for 2 hours, the cells were washed, dissolved, and counted as described above for binding studies. The medians of triplicate experiments, which usually varied from their means by less than 5%, were used to calculate ECSOS, the concentration necessary for half-maximal displacement.
RESULTS
Our goal is to develop toxin-based therapies for diseases that are not curable by conventional chemotherapy. For this to be successful the cells must contain unique growth factor receptors or other antigens on their surface. Because cells from patients with CLL contain IL-2 re~eptors,3,~ we chose to examine the malignant cells from 14 patients with CLL for their sensitivity to several chimeric toxins. These toxins contain anti-Tac(Fv), the combining site of an antibody directed at the p55 subunit of the IL-2 receptor. Table 1 shows the clinical characteristics of the patients. Patient 1 had the prolymphocytic variant of CLL. All patients had B-cell disease, based on positive FACS staining for CD19 and CD20 (data not shown). Patients ranged in age from 52 to 78. White blood cell (WBC) counts ranged from 10,500 to 306,000/mm3. In all patients, the vast majority of the cells were lymphocytes, by light microscopical examination of Wright-stained cytospins of the cells (data not shown). The patients were evenly divided with respect to stage of disease, with 5 patients having A, 5 patients having B, and 4 patients having C disease, according to the Binet staging system.27 Over half of the patients were untreated at the time blood Displacement assay.
Patient characteristics.
was obtained, while the others were treated with chemotherapy. Cells from patients 1 and 2 were examined twice for toxin sensitivity, with 17 and 15 months separating the two assays, respectively. During the second assay, patient 1 was untreated and patient 2 was treated with fludarabine. Cells from patients 5 and 7 through 9 were examined twice over 1 to 5 months, and during this time the treatment did not vary significantly.
The cytotoxic effect of anti-Tac(Fv)-PE40 and anti-Tac(Fv)-PE40KDEL was evaluated by incubating cells from patients with CLL with the recombinant toxins for 60 hours and pulse labeling the cells for 6 to 8 hours with [3H]-leucine. Table 2 shows that anti-Tac(Fv)-PE40KDEL was very cytotoxic toward cells from half (7 of 14) of the patients. The ICSDs varied from 1.2 to 9 ng/mL for patients with sensitive cells. Cells from patient 1 showed an ICso of 9 ng/mL during the first assay, and 1.2 ng/mL 17 months later. Cells from patient 2 were also assayed twice, 15 months apart, and the ICSOs were 1.5 and 3 ng/mL. For patients 1 and 2, cytotoxicity curves are depicted in Figs 2 A and B, respectively, for the first assays. In cells from patient 1, anti-Tac(Fv)-PE40KDEL at 100 ng/mL resulted in just over 50% inhibition of protein synthesis for the first assay (Fig 2A) , but greater than 85% inhibition for the second assay (data not shown). Cells from patients 7 through 12 were resistant to anti-Tac(Fv)-PE40KDEL, showing less than 50% inhibition of protein synthesis even at 1,000 ng/mL (Table 2, Fig 2, G through  L) . With anti-Tac(Fv)-PE40, the ICs0s for cells of patients 2 and 6 were 500 and 40 ng/mL, respectively, and greater than 1,000 ng/mL for the other 12 patients (data not shown). Thus, anti-Tac(Fv)-PE40KDEL was very cytotoxic toward cells from half of the 14 CLL patients, and was much more effective than anti-Tac(Fv)-PE40.
Activity of anti-Tac(Fv)-PE40ZCDEL.
For 
Activity of DT388-anti-Tac(Fv).
In an identical manner, cells from the 14 patients with CLL were evaluated for their response to DT388-anti-Tac(Fv). Table 2 shows the IC5,+ toward each of the 14 CLL samples and the normal sample. Figure 2 compares the cytotoxicity curves of anti-Tac(Fv)-PE40KDEL and DT388-anti-Tac(Fv) for these samples. The data show that cells from 11 of the 14 patients were sensitive to DT388-anti-Tac(Fv). Cells from patients 2 through 6, 8, 9, 11, and 13 were very sensitive, with IC5,,s ranging from less than 1 to 16 ng/mL. Cells from patients 12 and 14 were less sensitive, with IC5,,s of 95 and 250 ng/mL, respectively. Cells from patient 2 were much less sensitive to DT388-anti-Tac(Fv) the second time they were tested, with an IC50 of 60 ng/mL (Table 2) . Patient 2 was being treated with fludarabine during the second but not the first assay. Interestingly, cells from patient 6, who was also being treated with fludarabine, were also much more sensitive to anti-Tac(Fv)-PE40KDEL than DT388-anti-Tac(Fv). Cells from patients 5 , 8 , and 9 were tested twice with DT388-antiTac(Fv) over 1 to 5 months, and IC5"s varied by only a few-fold (Table 2 ). Cells from patient 1 with prolymphocytic leukemia were very sensitive to anti-Tac(Fv)-PE40KDEL but resistant to DT388-anti-Tac(Fv) on two separate occasions (Table 2 , Fig 2A) . The resistance of cells from patients 7 and 10 to DT388-anti-Tac(Fv) was also confirmed by more than one assay (data not shown).
Correlation between inhibition of protein synthesis and cell death. To determine whether greater than 50% inhibition of protein synthesis indicated that greater than 50% of the cells were killed, we used trypan blue which stains cells with nonfunctional cell membranes. We examined the cells 1 week after the addition of toxins by light microscopy, and counted the cells that were still able to extrude the dye. We tested cells from patients 1,2, and 13, and found that those cells sensitive to anti-Tac(Fv)-PI?AOKDEL or DT388-antiTac(Fv) by protein synthesis were also sensitive by the viability assay. Moreover, at a given toxin concentration (1, 10, or 100 ng/mL), the percent of cell death was greater than the percent of inhibition in protein synthesis. Conversely, cells from patient 1 were resistant to DT388-antiTac(Fv) by both assays. Thus, inhibition of protein synthesis in the CLL cells by recombinant immunotoxins correlated with cell death.
To determine the activity of a DT derivative directed by IL-2, we tested DT388-IL-2 toward cells from 13 of the 14 CLL patients. Table 2 shows that cells from 9 of the 13 patients were not affected by DT388-IL-2. There was a small cytotoxic effect on the cells from four patients, with ICS0s ranging from 100 to 550 ng/mL. The remaining nine patients showed no significant response, even at 1,000 ng/mL. Thus, DT388-IL-2 was not an effective cytotoxic agent against these cells.
Cytotoxic spec@city. We performed several control experiments to prove that the cytotoxicity of anti-Tac(Fv)-PE40KDEL and DT388-anti-Tac(Fv) was specific and required both binding and ADP-ribosylation activity. To determine if only binding of anti-Tac(Fv) to the p55 subunit was responsible for the cytotoxicity of the recombinant toxins, we incubated cells from each patient with anti-Tac at 2,500 ng/mL, and found no significant cytotoxicity (data not shown). This indicates that the binding of the antibody variable region is insufficient for cytotoxicity. To determine if the activity of antbTac(Fv)-PE40KDEL required ADP ribosylation activity, we tested the cells with anti-Tac(Fv)-PE40KDELASp553. This molecule, depicted in Fig 1, has no ADP ribosylation activity because of mutation of Glu553 to a~p a r t a t e .~~ It still binds like the active toxin, as evidenced by its ability to compete for the cytotoxicity of anti-Tac(Fv)-PE40KDEL on HUT-102 cells (data not shown). Moreover, it probably internalizes like the active toxin, because PED553 was shown to internalize and translocate the same fragments to the cytosol as wild type PE.8 Anti-Tac(Fv)-PE40KDELASp553 was tested on cells from all 14 patients and in each case showed no cytotoxicity (data not shown), indicating that cytotoxicity of anti-Tac(Fv)-PE40KDEL required ADP ribosylation activity. To ascertain that cytotoxicity also required binding to the p55 subunit of the IL-2 receptor, we performed competition experiments using the anti-Tac antibody at 2,500 ng/mL to block binding of either anti-Tac(Fv)-PE40KDEL or DT388-anti-Tac(Fv). Figure 3 shows the results of competition experiments performed on cells from patients 2 and 11. In each case, 2,500 ng/mL of anti-Tac but not 2,500 ng/mL of the irrelevant IgG 2a control antibody LL2= effectively blocked the cytotoxic activity of DT388-anti-Tac(Fv). Similarly, in cells from patients 1 and 2, anti-Tac at 2,500 ng/mL blocked the cytotoxic activity of anti-Tac(Fv)-PE40KDEL (data not shown). Thus, cytotoxicity of the recombinant toxins required them to bind to p55 on the CLL cells, internalize, and ADP ribosylate EF2 in the cytoplasm.
To quantitate the numbers of p55 subunits per cell from CLL patients, we performed binding studies using [3H]-anti-Tac. Aliquots of cells (0.2 mL/well) were incubated for approximately 2 hours at 4°C with increasing amounts of [3H]-anti-Tac in the presence and absence of a 1,000-fold excess of unlabeled humanized anti-Ta~.*~ The choice of the humanized form of anti-Tac was made based on availability from the company. After washing and dissolving the cells, the bound antibody was quantitated on a scintillation counter. Figure  4A Table 2 lists receptor numbers for the 10 patients tested; patient 1 has about 1,000 receptors per cell. Figure 4 , C and D, show similar data for patient 5, who also had 1,000 receptors/cell. For patients 2, 7, and 8, receptor numbers were determined twice, in assays performed several weeks apart. Table 2 shows that the two measurements of receptor number for these patients are less than twofold different. Thus, CLL cells from 8 of the 10 patients had 400 to 1,500 p55 subunits per cell. The dissociation constants (kds) were all between 1.0 and 3. For personal use only. on October 30, 2017. by guest www.bloodjournal.org From improved less than 2.5-fold. The cells did not lose sensitivity with time. Thus, to examine the cytotoxic effect of either recombinant toxin against cells from CLL patients, the 60-hour incubation was most appropriate.
DISCUSSION
We are interested in the use of recombinant toxins composed of anti-Tac(Fv) for the treatment of malignancies or autoimmune diseases where the target cells express the p55 subunit of the IL-2 receptor. In the current study, we found that cells from 7 of 14 patients with CLL were very sensitive to anti-Tac(Fv)-PE40KDEL (ICs0 I 16 ng/mL). Cells from 9 of the 14 patients were very sensitive to DT388-anti-Tac(Fv), and cells from an additional two patients showed a weak response to this recombinant toxin. In contrast, DT388-IL-2 or anti-Tac(Fv)-PE40 were much less effective at killing cells from CLL patients.
Sensitivity of CLL cells to anti-Tac(Fv)-PE4OKDEL or DT388-anti-Tac(Fv). We found that cells from 11 of 14 patients were sensitive to DT388-anti-Tac(Fv), while cells from 7 of 14 patients were sensitive to anti-Tac(Fv)-PE40KDEL. Cells from six of the patients were very sensitive to both toxins. Cells from five patients were over 10-fold more sensitive to DT388-anti-Tac(Fv) than to anti-Tac(Fv)-PE40KDEL, while cells from two patients were greater than 10-fold more sensitive to anti-Tac(Fv)-PE40KDEL. In contrast, HUT-102 cells and samples of fresh cells from ATL patients were more sensitive to anti-Tac(Fv)-PE40KDEL than DT388-anti-Tac(Fv) (unpublished data, 1991-1992) . The binding data (Table 3) shows that differences in affinity for p55 cannot explain the cytotoxicity difference between these two molecules on CLL cells. Therefore, the difference in activity between anti-Tac(Fv)-PE40KDEL and DT388-Tac(Fv) must be caused by differences in the efficiency with which each of the two recombinant toxins are metabolized by the target cell. For a recombinant toxin to kill a cell it must enter the cell by endocytosis, and be processed to an active fragment that is translocated to the cytosol.8 It is possible that either the protease necessary to process PEs or the protease needed to process DT1' is absent in cells from some CLL patients. Alternatively, the carboxyl terminal sequence of anti-Tac(Fv)-PE40KDEL or the amino terminal sequence of DT388-anti-Tac(Fv), both of which are important for cytotoxicity but not ADP ribosylation a~t i v i t y ,~~,~~ may not be functional in cells from some patients. Regardless of the basis for differential toxicity, anti-Tac(Fv)-PE40KDEL and DT388-anti-Tac(Fv) might broaden the spectrum of activity of recombinant toxins toward CLL.
We found that DT388-IL-2 had little if any cytotoxic activity toward cells from CLL patients (Table 2) . We also tested IL-2-PE4E on four patient samples and found no sensitivity in cells from patients 1 and 12 through 14 (data not shown). IL-2-PE4E contains full-length PE carrying four mutations in domain Ia to abolish binding to the PE receptor.29 It is very cytotoxic to HUT-102 cells (ICs0 = 2 ng/~nL),~O but is much less cytotoxic than anti-Tac(Fv)-PE40 toward fresh cells from ATL patients.ls We have recently found that fresh cells from ATL patients are often much less sensitive to DT388-IL-2 than to DT388-anti-Tac(Fv) (unpublished data, 1990-1992) . It is possible that malignant PBMCs from CLL patients have very low numbers of high affinity IL-2 receptors, and IL-2 toxins must bind to the p55 subunits. If so, the difference in the kds of anti-Tac(Fv) (-10-Io mol/L) and IL-2 ( -mol/L) for binding to ~5 5~~2~' may lead to the difference in cytotoxicity of DT388-anti-Tac(Fv) and DT388-IL-2 toward those cells.
The DT388-IL-2 used in our study is very similar to DAB389IL-2, which has been described previously,20 and is likely to have the same cytotoxic activity. DAB3891L-2 was reported to be fourfold more cytotoxic than DAB4861L-220; the ICso of DAB4861L-2 on HUT-102 cells was reported to be about 1.5 r~g / m L ,~~ which is a few-fold higher than our ICs0 for DT388-IL2 in a similar assay. Between Thr-386 of DT and Pro-2 of IL-2 (where the glycine that follows methionine is considered the first amino acid of DT), DT388-IL-2 contains the amino acids RPHMAD,22 while DAB3891L-2 contains HA." Also, DT388-IL-2 contains the extra amino acids IPEGEA following amino acid 131 of IL-2.22 It is interesting that DAB4861L-2 in a clinical trial has resulted in a partial remission in a CLL ~a t i e n t .~ Perhaps the malignant cells in that patient had high numbers of high affinity IL-2 receptors. It is also possible that the clonogenic cells responsible for malignant cell proliferation in CLL have higher numbers of IL-2 receptors than do cells found in the peripheral blood of such patients.
We have previously shown that anti-Tac(Fv)-PE40KDEL, which contains -KDEL following amino acid 608 of PE, is several-fold more cytotoxic toward cell lines than anti-Tac(Fv)-PE40. 19 Moreover, anti-Tac(Fv)-PE40KDEL was several-fold more cytotoxic than anti-Tac(Fv)-PE40 toward fresh ATL cells (unpublished data, 1990-1992) . It is unclear why the ICso for anti-Tac(Fv)-PE40 was greater than 20-fold more than that of anti-Tac(Fv)-PE40KDEL on cells from CLL patients 2 and 6, and is greater than 1,000 ng/mL on cells from the remaining 12 CLL patients (data not shown). The binding data in Table 3 indicate that both recombinant toxins bind with equal affinity to p55. Moreover, previous data indicate that changes in amino acids past position 602 of PE do not affect ADP ribosylation activity.24 We believe the carboxyl terminus delivers PE to a cellular compartment where translocation of the enzymatic portion of the toxin into the cytoplasm occurs, and that this process is more efficient Targeting CLL with ZL-2.
Importance of the carboxyl terminus of PE.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From with -KDEL than the native -REDLK sequence at the carboxyl terminus. It is possible that the -REDLK carboxyl terminus leads the toxin to a different, less efficient pathway toward translocation than -KDEL; this -REDLK pathway may be missing in cells from most CLL patients. Alternatively, both the -REDLK and -KDEL pathways may be present in CLL cells, but a recombinant toxin using the less efficient pathway for translocation may not kill the cell even if it saturates the relatively few binding sites.
Cells from 2 of the 14 patients tested were not sensitive to any of the toxins used ( Table 2, Fig 2, G and J) . One of these had less than 100 p55 subunits per cell. The other had about 700 receptors. Low receptor numbers probably contributed to resistance in at least the former case. Normal PBMCs were also resistant to all active toxins tested. In addition to the data shown in Table 2 , we tested several other normal samples of PBMCs and Ficoll-purified BM cells, and found no sensitivity to the toxins in concentrations up to 10,000 ng/mL (data not shown).
Cells not sensitive to toxins.
CONCLUSION
We have shown that anti-Tac(Fv)-PE40KDEL and DT388-anti-Tac(Fv) are effective in killing malignant PBMCs from a high percentage of CLL patients, despite the presence of low numbers of receptors on those cells. These recombinant immunotoxins appear much more effective than either DT388-IL-2 or anti-Tac(Fv)-PE40. The clinical utility of these molecules will depend on how the malignant progenitor cells in CLL patients differ from malignant PBMCs from patients, and how toxic the immunotoxins are in humans. Based on our data, we believe anti-Tac(Fv)-PE40KDEL and DT388-anti-Tac(Fv) should be studied further as potential agents for the treatment of CLL.
